Browsing by Author "Collins, Jeremy D."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study
    (Elsevier, 2024-01-16) Nassar, Amin H.; El-Am, Edward; Denu, Ryan; Alaiwi, Sarah Abou; El Zarif, Talal; Macaron, Walid; Abdel-Wahab, Noha; Desai, Aakash; Smith, Caleb; Parikh, Kaushal; Abbasi, Muhannad; Farhat, Elias Bou; Williams, James M.; Collins, Jeremy D.; Al-Hader, Ahmad; McKay, Rana R.; Malvar, Carmel; Sabra, Mohamad; Zhong, Caiwei; El Alam, Raquelle; Chehab, Omar; Lima, Joao; Phan, Minh; Pria, Hanna Ferreira Dalla; Trevino, Alexandra; Neilan, Tomas G.; Kwan, Jennifer M.; Ravi, Vinod; Deshpande, Hari; Demetri, George; Choueiri, Toni K.; Naqash, Abdul Rafeh; Medicine, School of Medicine
    Background: Primary cardiac soft tissue sarcomas (CSTS) affect young adults, with dismal outcomes. Objectives: The aim of this study was to investigate the clinical outcomes of patients with CSTS receiving immune checkpoint inhibitors (ICIs). Methods: A retrospective, multi-institutional cohort study was conducted among patients with CSTS between 2015 and 2022. The patients were treated with ICI-based regimens. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates were determined according to Response Evaluation Criteria in Solid Tumors version 1.1. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events version 5.0. Results: Among 24 patients with CSTS, 17 (70.8%) were White, and 13 (54.2%) were male. Eight patients (33.3%) had angiosarcoma. At the time of ICI treatment, 18 patients (75.0%) had metastatic CSTS, and 4 (16.7%) had locally advanced disease. ICIs were administered as the first-line therapy in 6 patients (25.0%) and as the second-line therapy or beyond in 18 patients (75.0%). For the 18 patients with available response data, objective response rate was 11.1% (n = 2 of 18). The median PFS and median OS in advanced and metastatic CSTS (n = 22) were 5.7 months (95% CI: 2.8-13.3 months) and 14.9 months (95% CI: 5.7-23.7 months), respectively. The median PFS and OS were significantly shorter in patients with cardiac angiosarcomas than in those with nonangiosarcoma CSTS: median PFS was 1.7 vs 11 months, respectively (P < 0.0001), and median OS was 3.0 vs 24.0 months, respectively (P = 0.008). Any grade treatment-related adverse events occurred exclusively in the 15 patients with nonangiosarcoma CSTS (n = 7 [46.7%]), of which 6 (40.0%) were grade ≥3. Conclusions: Although ICIs demonstrate modest activity in CSTS, durable benefit was observed in a subset of patients with nonangiosarcoma, albeit with higher toxicity.